CSL scores world-first approval

Posted 30 November 2023 AM

CSL has landed its first regulatory approval for its new self-amplifying messenger RNA technology.

This week Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, for initial vaccination and booster for adults 18 years and older.

To see the whole article, please login

Popular

Bracing for a $100M revenue hit

$30M quarterly sales left behind

TGA first to add new mRNA jab AE

Thumbs down for pharma websites

Latest Jobs

Commercial Analyst

Senior Customer Service Representative

Account Manager

GP Sales Representative

See all...

Pharma in Focus Jobs

Sales & Customer Relations (27)

Clinical & Medical, R&D (18)

Regulatory, Pharmacovigilance & QA (7)

Other (25)

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now